|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
OCCLs were evaluated in terms of proliferation, migration, invasion and BRAF V600E point mutation assays.
|
29291435 |
2018 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, in multivariate COX analysis, the association remained significant only for CA125 levels (vs. ⩽ 35 u/ml group, HR 3.341; 95% CI, 1.198-9.316; P= 0.0212), vascular invasion (vs. negative vascular invasion, HR, 2.349; 95% CI, 1.227-4.499; P= 0.01), and BRAF (V600E) (vs. wild Braf, HR, 7.794; 95% CI, 1.867-32.531; P= 0.0049).
|
29562502 |
2018 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
One case not meeting criteria for NIFTP maintained the diagnosis of encapsulated FVPTC without invasion but demonstrated significant mitotic activity (three mitoses/ten HPF) and lacked lymph node metastases and BRAF V600E mutation.
|
29368294 |
2018 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway.
|
29371951 |
2017 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
By immunohistochemistry, TENM1 expression in papillary thyroid cancer was associated with the classical subtype (p = 0.018), extrathyroidal invasion (p = 0.001), BRAF V600E mutation (p < 0.001), and an advanced stage (p = 0.019).
|
28004221 |
2017 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
The combinatorial treatment of PLX4032 and PHA665752, a c-Met inhibitor reversed EMT.Similar results were confirmed in vivo. c-Met-mediated reactivation of the PI3K/AKT pathway contributes to the drug resistance to PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer cells and further promotes tumor cell migration and invasion by upregulated EMT mechanism.
|
27880942 |
2017 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
In functional experiments, Nthy/V600E showed increased anchorage-independent growth and invasion through Matrigel, compared to Nthy/WT.
|
28031237 |
2017 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis confirmed significant associations between BRAF(V600E) mutation and female gender, multifocality, ETE, LNM, TNM stage, concomitant hashimoto thyroiditis, vascular invasion and recurrence/persistence, suggesting the predictive value of BRAF(V600E) mutation for PTC prognosis.
|
26871894 |
2016 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Coexistence of BRAF V600E and TERT promoter mutations was particularly associated with high-risk clinicopathological features, as exemplified by extrathyroidal invasion seen in 54.5% (12/22) of patients harboring both mutations versus 9.9% (23/232) of patients harboring neither mutation (P < 0.001).
|
26943032 |
2016 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
The pooled analysis indicated that age<45 years (OR = 1.57, 95%CI:1.48-1.66, P < 0.001), male gender (OR = 1.79, 95%CI: 1.69-1.91, P < 0.001), tumor size>10 mm (OR = 2.61, 95%CI:2.27-3.00, P < 0.001), bilaterality (OR = 1.52, 95%CI:1.31-1.77, P < 0.001), multifocality (OR = 1.46, 95%CI: 1.31-1.61, P < 0.001), extracapsular invasion (OR = 2.10, 95%CI:1.81-2.43, P < 0.001), angiolymphatic invasion (OR = 8.02, 95%CI:5.00-12.87, P < 0.001), high histologic risk (OR = 2.62, 95%CI:2.13-3.22, P < 0.001) and BRAF(V600E) mutation (OR:1.78, 95%CI:1.38-2.30, P < 0.001) were significantly associated with CLNM, and upper third location (OR = 0.54, 95%CI:0.43-0.67, P < 0.001) and lymphocytic thyroiditis (OR = 0.64, 95%CI:0.42-0.97, P = 0.034) were decreased risk factors of CLNM.
|
26944586 |
2016 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thirteen PTCs had the B-Raf proto-oncogene, serine/threonine kinase (BRAF) valine-to-glutamic acid mutation at position 600 (BRAF(V) (600E)) (13 of 27 tumors; 48%), 11 measured <2 cm, and 6 had lymphatic invasion (46%), with vascular invasion in 3.
|
26784937 |
2016 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found significant association between BRAF (V600E) mutation and age (P < 0.0001), extrathyroidal invasion (P = 0.017), lymph node metastasis (P = 0.038) and TNM stage III/IV (P = 0.001).
|
27387551 |
2016 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results provide support for the role of BRAF(V600E) in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma.
|
27210749 |
2016 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Doxycyclin-inducible knockdown of endogenous B-Raf(V600E) decreases cellular motility and invasion in conventional and three-dimensional (3D) culture, whereas it promotes cell-cell contacts and induces various hallmarks of differentiated epithelia.
|
25381152 |
2015 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dual inhibition of BRAF(V600E) and MEK reduced but did not prevent SW1736 invasion although rebound phosphorylation of ERK in response to PLX4720 was blocked by U0126.
|
26384551 |
2015 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
We find that metastatic BRAF(V600E)-PTC cells elicit paracrine-signaling which trigger migration of pericytes, blood endothelial cells and lymphatic endothelial cells as compared to BRAF(WT)-PTC cells, and show a higher rate of invasion.
|
26636651 |
2015 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we report that guanosine monophosphate synthase (GMPS), an enzyme required for the de novo biosynthesis of GMP, has a major role in invasion and tumorigenicity of cells derived from either BRAF(V600E) or NRAS(Q61R) human metastatic melanomas.
|
25909885 |
2015 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no significant association between BRAF(V600E) mutation and sex, histologic type, the Clark level, the Breslow index, solar elastosis, angiolymphatic and perineural invasion, satellitosis, and coexisting nevus.
|
24471189 |
2014 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, proliferation and invasion assays were conducted using cell lines. miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regulated miRNA in CRCs with mutated BRAF (V600E) compared with CRCs possessing wild-type BRAF (including cases with KRAS mutation).
|
24242331 |
2014 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
Considering all tumor foci, the all BRAF(V600E) mutation group exhibited a younger population (P = .039), showed increased extrathyroidal invasion (38.8% vs 14.7%, P = .017) and lymph node metastasis (71.4% vs 48.4%, P = .038), and received more radioactive iodine therapy (79.2% vs 52.9%, P = .012) than the mixed BRAF(V600E) mutation group.
|
24612623 |
2014 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
We concluded that the presence of BRAF(V600E) could be preoperatively predictive of extrathyroidal invasion in a Chinese population.
|
25400776 |
2014 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was significantly associated with male sex, tumor size, extrathyroidal invasion, nodal metastasis, and advanced tumor stage (p < .05).
|
22488961 |
2013 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) causes upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1), which promotes cell invasion in papillary thyroid carcinoma (PTC).
|
23893334 |
2013 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
One-hundred and twenty-nine papillary thyroid microcarcinomas were tested for BRAF(V600E) mutation by single-strand conformation polymorphism, and their clinicopathologic features (age, sex, tumor size, multifocality, nodal metastases, histologic subtype, tumor cell morphology, architecture, tumor-associated stromal reaction, tumor interface to non-neoplastic thyroid (well circumscribed vs infiltrative), extrathyroidal extension, lymphovascular invasion, intratumoral multinucleated giant cells, and adjacent non-neoplastic thyroid pathology) were examined.
|
22918165 |
2013 |
|
Tumor Cell Invasion
|
|
0.100 |
GeneticVariation
|
BEFREE |
In contrast, age- and size-matched classic papillary microcarcinomas (n=26) showed no extrathyroidal extension (p=0.002), lymphovascular invasion in 1, central compartment lymph node metastasis in 2, lateral cervical node metastasis in 1, multifocal tumors in 10 (38.5%), the BRAF(V600E) mutation in 20 (76.9%), and it infrequently presented in stage III/IVA (7.7%, p=0.02).
|
23682579 |
2013 |